Literature DB >> 21764262

Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.

Coralie M Vallet1, Béatrice Marquez, Eva Ngabirano, Sandrine Lemaire, Marie-Paule Mingeot-Leclercq, Paul M Tulkens, Françoise Van Bambeke.   

Abstract

Fluoroquinolones enter eukaryotic cells but the correlation between cellular accumulation and activity remains poorly established. Gemifloxacin is known to accumulate to a larger extent than most other fluoroquinolones in tissues. Using murine J774 macrophages and human THP-1 monocytes, we show that gemifloxacin accumulates more than ciprofloxacin and even moxifloxacin. Whilst showing indistinguishable kinetics of accumulation in J774 macrophages, gemifloxacin was released at an approximately two-fold slower rate than ciprofloxacin and its release was only partial. Gemifloxacin was also a weaker substrate than ciprofloxacin for the efflux transporter Mrp4 active in J774 macrophages. In cells infected with Listeria monocytogenes or Staphylococcus aureus (typical cytoplasmic and phagolysosomal organisms, respectively), gemifloxacin was equipotent to moxifloxacin and ciprofloxacin in concentration-dependent experiments if data are normalised based on the minimum inhibitory concentration (MIC) in broth. Thus, larger cellular concentrations of gemifloxacin than of moxifloxacin or ciprofloxacin were needed to obtain a similar target effect. Fractionation studies showed a similar subcellular distribution for all three fluoroquinolones, with approximately two-thirds of the cell-associated drug recovered in the soluble fraction (cytosol). These data suggest that cellular accumulation of fluoroquinolones is largely a self-defeating process as far as activity is concerned, with the intracellular drug made inactive in proportion to its accumulation level. Whilst these observations do not decrease the intrinsic value of fluoroquinolones for the treatment of intracellular infections, they indicate that ranking fluoroquinolones based on cell accumulation data without measuring the corresponding intracellular activity may lead to incorrect conclusions regarding their real potential.
Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21764262     DOI: 10.1016/j.ijantimicag.2011.05.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

1.  Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

2.  Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages.

Authors:  Frédéric Peyrusson; Deborah Butler; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

3.  RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.

Authors:  Julien M Buyck; Frédéric Peyrusson; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

4.  The effect of ciprofloxacin on doxorubicin cytotoxic activity in the acquired resistance to doxorubicin in DU145 prostate carcinoma cells.

Authors:  Asieh Davary Avareshk; Jamileh Gholami; Razieh Jalal
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

5.  Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

6.  Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy.

Authors:  Jennifer S Guimbellot; Kevin J Ryan; Justin D Anderson; Zhongyu Liu; Latona Kersh; Charles R Esther; Steven M Rowe; Edward P Acosta
Journal:  J Cyst Fibros       Date:  2020-02-07       Impact factor: 5.482

7.  Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity.

Authors:  Béatrice Marquez; Vincent Pourcelle; Coralie M Vallet; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Jacqueline Marchand-Bruynaert; Françoise Van Bambeke
Journal:  Pharm Res       Date:  2013-12-05       Impact factor: 4.200

8.  ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines.

Authors:  Géraldine Dessilly; Laure Elens; Nadtha Panin; Arnaud Capron; Anabelle Decottignies; Jean-Baptiste Demoulin; Vincent Haufroid
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

9.  Bactericidal and Anti-biofilm Effects of Polyhexamethylene Biguanide in Models of Intracellular and Biofilm of Staphylococcus aureus Isolated from Bovine Mastitis.

Authors:  Nor F Kamaruzzaman; Stacy Q Y Chong; Kamina M Edmondson-Brown; Winnie Ntow-Boahene; Marjorie Bardiau; Liam Good
Journal:  Front Microbiol       Date:  2017-08-11       Impact factor: 5.640

10.  Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.

Authors:  Frédéric Peyrusson; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.